Driehaus Capital Management LLC Decreases Position in Structure Therapeutics Inc. (NASDAQ:GPCR)

Driehaus Capital Management LLC decreased its position in shares of Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) by 18.6% during the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 2,057,410 shares of the company's stock after selling 469,020 shares during the period. Driehaus Capital Management LLC owned 3.59% of Structure Therapeutics worth $55,797,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of GPCR. ANTIPODES PARTNERS Ltd increased its position in shares of Structure Therapeutics by 115.0% in the fourth quarter. ANTIPODES PARTNERS Ltd now owns 1,034 shares of the company's stock worth $28,000 after acquiring an additional 553 shares in the last quarter. GAMMA Investing LLC boosted its position in Structure Therapeutics by 4,155.6% during the 4th quarter. GAMMA Investing LLC now owns 1,149 shares of the company's stock worth $31,000 after purchasing an additional 1,122 shares during the period. FNY Investment Advisers LLC acquired a new stake in Structure Therapeutics in the 4th quarter valued at $40,000. Virtus ETF Advisers LLC raised its position in Structure Therapeutics by 25.5% in the fourth quarter. Virtus ETF Advisers LLC now owns 2,242 shares of the company's stock valued at $61,000 after purchasing an additional 455 shares during the period. Finally, Assetmark Inc. lifted its stake in shares of Structure Therapeutics by 72.3% during the fourth quarter. Assetmark Inc. now owns 2,271 shares of the company's stock worth $62,000 after purchasing an additional 953 shares in the last quarter. Institutional investors and hedge funds own 91.78% of the company's stock.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the stock. Citigroup initiated coverage on shares of Structure Therapeutics in a research note on Friday, May 2nd. They set a "buy" rating and a $60.00 price objective on the stock. William Blair assumed coverage on shares of Structure Therapeutics in a research report on Friday, February 28th. They set an "outperform" rating for the company. Stifel Nicolaus assumed coverage on Structure Therapeutics in a research note on Wednesday, January 8th. They issued a "buy" rating and a $50.00 price target for the company. Finally, HC Wainwright reiterated a "buy" rating and issued a $80.00 target price on shares of Structure Therapeutics in a research report on Tuesday, April 22nd. Nine investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus price target of $78.63.

Structure Therapeutics Stock Performance

Structure Therapeutics stock opened at $26.53 on Thursday. Structure Therapeutics Inc. has a 1 year low of $13.22 and a 1 year high of $62.74. The firm's 50 day moving average price is $20.78 and its two-hundred day moving average price is $27.19. The firm has a market cap of $1.52 billion, a price-to-earnings ratio of -35.86 and a beta of -1.69.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last announced its earnings results on Thursday, February 27th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.23) by $0.01. As a group, equities analysts predict that Structure Therapeutics Inc. will post -0.82 EPS for the current fiscal year.

Structure Therapeutics Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.